vida: extract 2 claims from commonwealth-fund-risk-adjustment-ma-explainer
- What: 2 new claims on MA risk adjustment mechanics and CMS reform structure - Why: Commonwealth Fund/CMS explainer January 2026 on risk adjustment gaming - Connections: deepens existing chart review exclusion claim with mechanical detail; introduces 70% OIG audit failure rate (not previously in KB) and frames V28 + chart review exclusion as structurally complementary (not redundant) reforms Pentagon-Agent: Vida <vida-agent>
This commit is contained in:
parent
ba4ac4a73e
commit
ce7e68dbb6
3 changed files with 94 additions and 1 deletions
|
|
@ -0,0 +1,37 @@
|
|||
---
|
||||
type: claim
|
||||
domain: health
|
||||
description: "OIG RADV audits of Medicare Advantage risk adjustment found 70% of submitted diagnosis codes unsupported by medical records, suggesting the MA payment system as a whole depends on codes that would not survive scrutiny at audit scale"
|
||||
confidence: likely
|
||||
source: "Commonwealth Fund risk adjustment explainer January 2026; CMS Risk Adjustment Data Validation (RADV) audit program findings"
|
||||
created: 2026-03-12
|
||||
depends_on:
|
||||
- "CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring"
|
||||
challenged_by: []
|
||||
---
|
||||
|
||||
# MA diagnosis codes fail OIG audit validation at 70 percent rate indicating systematic upcoding is the structural baseline not edge-case fraud
|
||||
|
||||
CMS Risk Adjustment Data Validation (RADV) audits — the program CMS uses to verify that diagnosis codes submitted by MA plans are supported by actual medical records — find that approximately 70% of submitted diagnosis codes are not supported by the records when audited. This is not a fringe finding from a single audit cycle; it reflects the structural operating reality of the MA risk adjustment system.
|
||||
|
||||
The MA payment mechanism works through the CMS-HCC (Hierarchical Condition Categories) model: CMS pays plans a monthly per-member capitation adjusted by risk scores derived from diagnosis codes. Each HCC carries a coefficient that increases payment for sicker patients. Plans submit diagnosis codes annually and CMS calculates risk scores from them. The financial incentive is direct: more diagnoses (or higher-severity diagnoses) map to higher risk scores which produce higher payments.
|
||||
|
||||
The 70% audit failure rate implies that the majority of MA's risk-adjusted payments above FFS baseline are grounded in codes that don't survive documentation review. This is not consistent with edge-case fraud by a handful of bad actors — it is consistent with industry-wide systematic upcoding as a standard operating practice. The gap between submitted codes and supportable codes represents the difference between what plans are paid and what they would be paid if CMS audited at scale.
|
||||
|
||||
The reason CMS has not audited at scale is structural. Full-scale RADV audits are expensive, legally contested (plans have challenged RADV methodology in court), and politically sensitive given the size of the MA market. The industry's continued dependence on unsupported codes is thus a rational response to a low-probability enforcement environment rather than a detection failure on CMS's part. If audit risk were priced accurately, the business models built around chart review and retrospective coding would be uneconomical.
|
||||
|
||||
The False Claims Act enforcement pattern corroborates the systemic picture: nearly every major MA plan has faced or settled DOJ upcoding allegations. The universality of enforcement exposure, not its exception, is the signal.
|
||||
|
||||
## Challenges
|
||||
|
||||
Plans and their consultants dispute RADV methodology, arguing that documentation gaps differ from fraudulent coding intent, and that some unsupported codes reflect documentation practices rather than deliberate inflation. The distinction between documentation failure and intentional upcoding is legally and empirically contested.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
- [[CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring]] — the specific regulatory response targeting the retrospective coding mechanisms that generate unsupported diagnoses
|
||||
- [[four competing payer-provider models are converging toward value-based care with vertical integration dominant today but aligned partnership potentially more durable]] — the acquisition-based integration model most dependent on coding arbitrage faces the greatest exposure if audit scale increases
|
||||
- [[Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening]] — purpose-built plans whose risk scores derive from genuine clinical encounters are structurally insulated from audit risk
|
||||
|
||||
Topics:
|
||||
- [[health/_map.md]]
|
||||
|
|
@ -0,0 +1,49 @@
|
|||
---
|
||||
type: claim
|
||||
domain: health
|
||||
description: "V28 reduces the universe of diagnoses that map to HCC payments (what gets coded) while the chart review exclusion eliminates retrospective coding not tied to clinical encounters (how it gets coded), making their combined savings effect additive and their combined structural impact the most significant MA reform since program inception"
|
||||
confidence: likely
|
||||
source: "Commonwealth Fund risk adjustment explainer January 2026; CMS V28 implementation documentation 2024-2026; CMS 2027 Advance Notice February 2026"
|
||||
created: 2026-03-12
|
||||
depends_on:
|
||||
- "CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring"
|
||||
challenged_by: []
|
||||
---
|
||||
|
||||
# V28 risk model update and 2027 chart review exclusion are structurally complementary reforms targeting coding breadth and coding method as distinct dimensions of MA upcoding
|
||||
|
||||
The two most significant CMS regulatory interventions in MA economics — the V24-to-V28 model transition and the proposed 2027 chart review exclusion — are often discussed as if they address the same problem. They do not. They target orthogonal dimensions of upcoding and their effects are additive, not redundant.
|
||||
|
||||
**V28 (implemented 2024–2026): What gets coded**
|
||||
|
||||
The V28 model update significantly decreased the number of diagnosis codes that map to HCCs (Hierarchical Condition Categories), while also increasing the total number of HCC categories. The practical effect: a narrower set of diagnoses triggers payment adjustments, and the diagnostic categories are more granular. Plans that submitted broad, lower-specificity diagnoses under V24 — capturing payment from codes that mapped loosely to HCCs — lose that revenue under V28. CMS estimated V28 would save $7.6 billion in 2024 alone, revealing the scale of payment generated by V24 diagnoses that V28 considers insufficiently specific to justify the uplift.
|
||||
|
||||
The V28 transition is being phased in over 2024–2026 with a full implementation by 2026. The phase-in is gradual to avoid abrupt market disruption, but the direction is clear: fewer diagnoses qualify for risk score credit, and those that do require higher specificity.
|
||||
|
||||
**2027 Chart Review Exclusion: How it gets coded**
|
||||
|
||||
The chart review exclusion proposal (CMS 2027 Advance Notice) targets a different variable: the method by which diagnoses are collected from patients. Specifically, diagnoses from "unlinked chart review records" — retrospective reviews of medical records not tied to a documented clinical encounter — would be excluded from risk score calculations. Diagnoses are allowed only when tied to an actual encounter.
|
||||
|
||||
This closes the retrospective coding loop. Under current rules, plans can review years of medical records to find additional codeable conditions and submit them for risk score credit regardless of whether any clinician documented those conditions during an actual patient visit. In-home health assessments — visits structured primarily to capture diagnosis codes rather than deliver care — are a related mechanism that the exclusion targets. The projected savings are more than $7 billion in 2027 from this exclusion alone.
|
||||
|
||||
**Why the complementarity matters**
|
||||
|
||||
V28 reduces the value of any given diagnosis code submission by narrowing what maps to payment. The chart review exclusion reduces the quantity of diagnosis codes that can be submitted by eliminating a major collection pathway. These are independent levers:
|
||||
|
||||
- A plan could adapt to V28 by shifting to higher-specificity diagnosis codes while continuing retrospective chart review. The chart review exclusion forecloses that adaptation.
|
||||
- A plan could adapt to the chart review exclusion by restricting retrospective coding to encounter-linked records. V28 simultaneously reduces the payment credit those encounter-linked codes generate.
|
||||
|
||||
The two reforms together constitute the most significant structural challenge to MA economics since the program's expansion — not because either is unprecedented alone, but because they close the system from two directions simultaneously. Industry warnings about benefit cuts and market exits emerge specifically from the combined pressure, not from either reform in isolation.
|
||||
|
||||
The V28 phase-in runs concurrently with the chart review exclusion proposal. By 2027, the MA coding landscape will have contracted both in the universe of mappable diagnoses (V28) and in the method by which diagnoses can be retrospectively captured (chart review exclusion). Plans whose economics depend on either lever face compounded pressure.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
- [[CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring]] — detailed mechanics of the chart review exclusion and its effect on vertical integration profit models
|
||||
- [[MA diagnosis codes fail OIG audit validation at 70 percent rate indicating systematic upcoding is the structural baseline not edge-case fraud]] — the scale of unsupported coding that both reforms target
|
||||
- [[Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening]] — purpose-built plans unaffected by either reform because their coding derives from genuine encounters
|
||||
- [[four competing payer-provider models are converging toward value-based care with vertical integration dominant today but aligned partnership potentially more durable]] — the dual reform accelerates the structural shift away from acquisition-based integration
|
||||
|
||||
Topics:
|
||||
- [[health/_map.md]]
|
||||
|
|
@ -7,7 +7,14 @@ date: 2026-01-01
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: report
|
||||
status: unprocessed
|
||||
status: processed
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-12
|
||||
claims_extracted:
|
||||
- "MA diagnosis codes fail OIG audit validation at 70 percent rate indicating systematic upcoding is the structural baseline not edge-case fraud"
|
||||
- "V28 risk model update and 2027 chart review exclusion are structurally complementary reforms targeting coding breadth and coding method as distinct dimensions of MA upcoding"
|
||||
enrichments:
|
||||
- "CMS 2027 chart review exclusion claim: V28 $7.6B savings figure and in-home health assessment mechanism could be added as supporting evidence"
|
||||
priority: high
|
||||
tags: [risk-adjustment, cms-hcc, upcoding, medicare-advantage, V28, chart-review]
|
||||
---
|
||||
|
|
|
|||
Loading…
Reference in a new issue